Search

Displaying results 3011 - 3020 of 10000 in total
  1. Drug

    Tafasitamab

    go.drugbank.com/drugs/DB15044
    ApprovedInvestigational

    [L15292,A191829] The CD19 surface protein is highly expressed on the surface of B-cells, where it appears to play a role in enhancing B-cell receptor signaling. … [L15307] It must be used in combination with [lenalidomide], as this combination results in greater efficacy as compared to either agent alone.[L15292]

    Categories: Lymphoma, B-Cell
  2. Drug

    Anifrolumab

    go.drugbank.com/drugs/DB11976
    ApprovedInvestigational

    Anifrolumab, or MEDI-546, is a type 1 interferon receptor (IFNAR) inhibiting IgG1κ monoclonal antibody indicated in the treatment of adults with moderate to severe systemic lupus erythematosus. … different definitions of autoantibody positivity, making comparison between trials difficult; all trials involve large portions of patients also using corticosteroids, which may alter patient responses in

    Categories: Type I Interferon Receptor AntagonistProducts: Saphnelo 300 mg/2 mL İnfüzyonluk Çözelti Hazırlamak İçin Konsantre, 1 ADET
  3. Drug

    Crinecerfont

    go.drugbank.com/drugs/DB18518
    ApprovedInvestigational

    [A264818] Crinecerfont was approved by the FDA in December 2024 as an adjunct to glucocorticoid replacement in patients with CAH.[L51973,L51993] … [A264818] Crinecerfont is a selective antagonist of corticotropin-releasing factor (CRF) type 1 receptor that works to reduce excessive ACTH secretion from the pituitary.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2B6 Substrates
  4. Drug

    Azacitidine

    go.drugbank.com/drugs/DB00928
    ApprovedInvestigational

    Azacitidine is a pyrimidine nucleoside analogue with anti-neoplastic activity. It differs from cytosine by the presence of nitrogen in the C5-position, key in its hypomethylating activity. … [A1415] The use of oral azacitidine for the treatment of AML in patients in complete remission was approved by the FDA in September 2020.[L35335]

    Synonyms: 4-amino-1-beta-D-ribofuranosyl-s-triazin-2(1H)-one, 5 AzacitidineCategories: Heterocyclic Compounds, 1-Ring
  5. Drug

    Foreskin fibroblast (neonatal)

    go.drugbank.com/drugs/DB10770
    Approved

    Also known as Dermagraft, this device is a cryopreserved human fibroblast-derived dermal substitute. … Composed of fibroblasts, extracellular matrix, and a bioabsorbable scaffold, it effectively supports wound healing [L2418].

  6. Drug

    Trichlormethiazide

    go.drugbank.com/drugs/DB01021
    ApprovedVet approved

    A thiazide diuretic with properties similar to those of hydrochlorothiazide. (From Martindale, The Extra Pharmacopoeia, 30th ed, p830)

    Categories: Heterocyclic Compounds, 2-Ring
  7. Drug

    Chloric acid

    go.drugbank.com/drugs/DB14150
    Approved

    Categories: Compounds used in a research, industrial, or household setting
  8. Drug

    Carprofen

    go.drugbank.com/drugs/DB00821
    ApprovedVet approvedWithdrawn

    Carprofen is a non-steroidal anti-inflammatory drug (NSAID) that is used by veterinarians as a supportive treatment for the relief of arthritic symptoms in geriatric dogs. … Carprofen was previously used in human medicine for over 10 years (1985-1995).

    Synonyms: (+/-)-2-(3-chloro-9H-carbazol-7-yl)propanoic acid, (±)-6-chloro-α-methylcarbazole-2-acetic acidCategories: Heterocyclic Compounds, 2-Ring, Heterocyclic Compounds, 3-Ring
  9. Drug

    Carisoprodol

    go.drugbank.com/drugs/DB00395
    Approved

    for abuse in addition to a low risk of dependence [L5074]. … Originally approved by the FDA in 1959 [FDA label], carisoprodol is a centrally acting muscle relaxant used in painful musculoskeletal conditions in conjunction with physical therapy and other medications

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C19 SubstratesSynonyms: N-isopropy-2-methyl-2-propyl-1,3-propanediol dicarbamate, (1-methylethyl)carbamic acid 2-(((aminocarbonyl)oxy)methyl)-2-methylpentyl ester
  10. Drug

    Artenimol

    go.drugbank.com/drugs/DB11638
    ApprovedInvestigational

    It was first authorized for market by the European Medicines Agency in October 2011 in combination with [DB13941] as the product Eurartesim. … Artenimol is an artemisinin derivative and antimalarial agent used in the treatment of uncomplicated *Plasmodium falciparum* infections [FDA Label].

    Mixtures: D-ARTEPP, D-ARTEPP DISPERSIBLECategories: Cytochrome P-450 CYP2C19 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors